INT114412

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 20
Disease Relevance 3.69
Pain Relevance 2.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
blood 1
muscle 1
parietal cells 1
stomach 1
knee 1
HCL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammatory mediators 42 99.90 Very High Very High Very High
Oxycodone 13 99.46 Very High Very High Very High
cINOD 10 99.34 Very High Very High Very High
Inflammation 114 99.06 Very High Very High Very High
transdermal 12 99.06 Very High Very High Very High
antagonist 55 98.12 Very High Very High Very High
backache 2 96.66 Very High Very High Very High
Osteoarthritis 2 96.22 Very High Very High Very High
qutenza 26 93.84 High High
calcitonin gene related peptide 48 88.84 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 149 99.70 Very High Very High Very High
Congenital Anomalies 3 99.60 Very High Very High Very High
Constipation 2 98.08 Very High Very High Very High
Low Back Pain 2 96.66 Very High Very High Very High
Osteoarthritis 2 96.32 Very High Very High Very High
Ulcers 6 93.44 High High
Gastroesophageal Reflux Disease 85 92.92 High High
Stress 5 92.84 High High
Pain 25 91.80 High High
Anxiety Disorder 1 85.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: A total of 690 patients were enrolled in this study; 437 (63.4%) received oxycodone HCl controlled-release and 253 (36.6%) received transdermal fentanyl.
Localization (release) of HCl
1) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0 Pain Relevance 0
CONCLUSION: Transdermal fentanyl and oxycodone HCl controlled-release both appear to be used by patients in a manner that is inconsistent with the standard recommendation in the manufacturers' PI;however, the difference between patient-reported utilization and the PI recommendation is more pronounced with oxycodone HCl controlled-release.


Localization (release) of HCl
2) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0 Pain Relevance 0
The inclusion criteria for the study were (1) diagnosis of chronic nonmalignant pain, (2) prescription for and current use of either transdermal fentanyl or oxycodone HCl controlled-release, and (3) duration of use for either transdermal fentanyl or oxycodone HCl controlled-release of at least 6 weeks.
Localization (release) of HCl
3) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0.07 Pain Relevance 0
The principal outcome measures were the average interval between oxycodone HCl controlled-release administrations, the number of days the current transdermal fentanyl patch would be worn, and the percentage of oxycodone HCl controlled-release and transdermal fentanyl patients whose administration frequency exceeded the standard recommendation in the manufacturer.s PI (every 12 hours for oxycodone HCl controlled-release or every 72 hours for transdermal fentanyl).
Localization (release) of HCl
4) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0 Pain Relevance 0
The inclusion criteria for the study were (1) diagnosis of chronic nonmalignant pain, (2) prescription for and current use of either transdermal fentanyl or oxycodone HCl controlled-release, and (3) duration of use for either transdermal fentanyl or oxycodone HCl controlled-release of at least 6 weeks.
Localization (release) of HCl
5) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0.07 Pain Relevance 0
CONCLUSION: Transdermal fentanyl and oxycodone HCl controlled-release both appear to be used by patients in a manner that is inconsistent with the standard recommendation in the manufacturers' PI;however, the difference between patient-reported utilization and the PI recommendation is more pronounced with oxycodone HCl controlled-release.


Localization (release) of HCl
6) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0 Pain Relevance 0
Patients completed either an oxycodone HCl controlled-release or transdermal fentanyl utilization questionnaire.
Localization (release) of HCl
7) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0.06 Pain Relevance 0
OBJECTIVE: To assess patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride (HCl) controlled-release among patients with chronic nonmalignant pain and to compare these patterns to standard dose administration guidelines recommended in the manufacturers. prescribing information (PI).
Localization (release) of HCl
8) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0.09 Pain Relevance 0
A conversion table was used to standardize opioid analgesic doses from transdermal fentanyl or oxycodone HCl controlled-release to daily oral morphine equivalents.
Localization (release) of HCl
9) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0.06 Pain Relevance 0
The average interval between administrations of oxycodone HCl controlled-release was 7.8 hours, and the median daily dose was 80.0 mg (mean 155.6 mg).
Localization (release) of HCl
10) Confidence 0.56 Published 2003 Journal J Manag Care Pharm Section Body Doc Link 14613465 Disease Relevance 0 Pain Relevance 0
INTRODUCTION: This pooled analysis of data from three phase 3 studies in patients with chronic osteoarthritis knee or low back pain evaluated the efficacy and tolerability of tapentadol prolonged release (PR; 100-250 mg twice daily) compared with placebo and oxycodone hydrochloride (HCl) controlled release (CR; 20-50 mg twice daily).
Localization (release) of HCl in knee associated with low back pain, oxycodone, osteoarthritis and backache
11) Confidence 0.56 Published 2010 Journal Adv Ther Section Abstract Doc Link 20556560 Disease Relevance 0.42 Pain Relevance 0.43
The presumed TRPV1 mitochondrial location inside parietal cells is in favour of the existence of a local pathway of auto-regulation of HCl secretion.
Localization (secretion) of HCl in parietal cells
12) Confidence 0.16 Published 2005 Journal Histochem. Cell Biol. Section Abstract Doc Link 16041554 Disease Relevance 0 Pain Relevance 0.14
Our aim was to identify which cell types express TRPV1 in the human stomach in order to gain a better insight in the role of this receptor in the regulation of HCl secretion.
Localization (secretion) of HCl in stomach
13) Confidence 0.16 Published 2005 Journal Histochem. Cell Biol. Section Abstract Doc Link 16041554 Disease Relevance 0 Pain Relevance 0.26
Furthermore, Kato et al. [7] demonstrated the inhibitory action of melatonin on secretion of HCL and pepsin.
Localization (secretion) of HCL
14) Confidence 0.09 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC2821302 Disease Relevance 0.62 Pain Relevance 0.14
The HCl-filled mucosal sac releases PAF into the supernatant41 and addition of a PAF receptor antagonist essentially abolished the supernatant-induced inhibition of neurally-mediated circular muscle contraction (Fig. 10).
Localization (releases) of HCl in muscle associated with antagonist
15) Confidence 0.07 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.31 Pain Relevance 0.21
To understand the inflammatory process in the esophagus it is important to establish which inflammatory mediators are released by HCl-stimulated esophageal mucosa at concentrations sufficient to attract and activate peripheral blood leukocytes.
Localization (released) of HCl in blood associated with inflammatory mediators and inflammation
16) Confidence 0.05 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.72 Pain Relevance 0.44
This indicates the existence of a self-perpetuating cycle of inflammation and motility abnormalities that is started by HCl-induced PAF release from the esophageal mucosa.
Localization (release) of HCl associated with inflammation and congenital anomalies
17) Confidence 0.05 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.48 Pain Relevance 0.20
We also discuss current alternative approaches being taken to mitigate the GI side-effects of NSAIDs, including developing combination drugs where NSAIDs are packaged with inhibitors of HCl secretion such as proton pump inhibitors or H2-receptor antagonists.
Localization (secretion) of HCl associated with antagonist and cinod
18) Confidence 0.05 Published 2009 Journal Drugs Today Section Abstract Doc Link 20135022 Disease Relevance 0.63 Pain Relevance 0.88
OBJECTIVE: To compare the risk of developing constipation between patients prescribed fentanyl transdermal system or oxycodone hydrochloride (HCl) controlled-release.
Localization (release) of HCl associated with oxycodone, transdermal and constipation
19) Confidence 0.04 Published 2004 Journal Consult Pharm Section Abstract Doc Link 16553474 Disease Relevance 0.17 Pain Relevance 0.26
Nonmedical use rates for KADIAN (morphine sulfate extended-release tablets), OxyContin (oxycodone HCl controlled-release tablets), Vicodin (hydrocodone bitartrate and acetaminophen tablets), and product-classes (morphine ER, oxycodone ER, and hydrocodone) were calculated.
Localization (release) of HCl
20) Confidence 0.03 Published 2008 Journal Clin J Pain Section Body Doc Link 18574362 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox